- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00659971
Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis
A Phase 2B Dose-Ranging Study of PAC113 Mouthrinse for Clinical and Microbial Evaluation in HIV Seropositive Individuals With Oral Candidiasis to Establish the Optimal Dose of PAC113
Study Overview
Detailed Description
This is a randomized, examiner-blinded, positive-controlled, parallel design clinical trial, which features 4 treatment arms. Forty-five (45)* HIV positive subjects per treatment arm will be recruited for 180 subjects total. The study includes 5 visits: a screening visit, a 14-day treatment phase with a baseline visit on Day 1, a Day 7 visit, a post-treatment visit 5 days after the last dose, and follow-up visit. During the screening visit subjects will be assessed for study eligibility. Eligible subjects will be randomized to 1 of the following treatment arms:
A. 0.15% PAC-113 mouthrinse (5 mL 4 times daily [q.i.d.]); B. 0.075% PAC-113 mouthrinse (5 mL q.i.d.); C. 0.0375% PAC-113 mouthrinse (5 mL q.i.d.); D. Nystatin oral suspension (100,000 units/mL; 5 mL q.i.d.) Subjects will be evaluated clinically for safety and severity of clinical signs and symptoms of oral candidiasis at baseline (Day 1), Day 7, Day 19 (5 days post-treatment) and Day 28 (follow-up visit). Subjects will also have a microbiological analysis performed at screening, and at Days 7, 19 and 28.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
North Carolina
-
Huntersville, North Carolina, United States, 28078
- Rosedale Infectious Disease
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Are male or female 18 to 65 years of age, inclusive
- Are able and willing to follow study procedures and instructions
- Are able to read, understand and sign an informed consent form
- Are documented as HIV positive
- Have pseudomembranous and/or erythematous oral candidiasis as confirmed by potassium hydroxide preparation of mucosal scraping
- Have a CD4 cell count performed prior to randomization or within 6 weeks prior to the screening visit
- Have a viral load performed prior to randomization or within 6 weeks prior to the screening visit.
- Both men and women who are active heterosexually must be willing to practice a medically accepted method of birth control.
Exclusion Criteria:
- Have received systemic antifungal therapy within 14 days of starting study
- Have received prior topical therapy for oral candidiasis within 7 days of starting study
- Have a concomitant fungal infection requiring systemic therapy
- Are currently receiving immunosuppressive therapy (e.g. corticosteroids), or cancer chemotherapy
- Female subjects who are pregnant (as determined by a positive serum or urine pregnancy test) or lactating, or female subjects who are of childbearing potential and who are not using hormonal or barrier methods of birth control (e.g., oral or parenteral contraceptives, diaphragm plus spermicide, condoms) or who have not characterized themselves as abstinent. Subjects who use hormonal contraceptives must have started the method at least 30 days prior to the screening examination
- Active substance abuse
- Have esophageal symptoms (dysphagia or odynophagia) unless esophageal candidiasis has been ruled out by endoscopy
- Have a life expectancy < 4 weeks
- Are currently receiving or have received an investigational agent in the last 30 days
- Have had a change in antiretroviral therapy within 14 days prior to study entry (this does not apply to dose adjustment of the same therapy)
Have any of the following laboratory abnormalities:
- White blood cell (WBC) count <1,500 cells/mm3
- Neutrophil granulocyte count <1,000 cells/mm3
- Hemoglobin <9.0/dL
- Transaminases (alanine aminotransferase [ALT] or aspartate aminotransferase [AST]) or bilirubin >3 times the upper limit of normal (ULN)
- Serum creatinine >2 times ULN
- Have peri-oral lesion (perleche) only
- Have oral manifestations of herpes simplex (active disease only), hairy leukoplakia and/or aphthous ulcers
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
PAC113 0,15% mouthrinse
|
PAC113 mouthrinse 0.15%; 0.075%; 0.0375% QID for 14 days
|
Experimental: 2
PAC113 0,075% mouthrinse
|
PAC113 mouthrinse 0.15%; 0.075%; 0.0375% QID for 14 days
|
Experimental: 3
PAC113 0,0375% mouthrinse
|
PAC113 mouthrinse 0.15%; 0.075%; 0.0375% QID for 14 days
|
Active Comparator: 4
Nystatin suspension
|
PAC113 mouthrinse 0.15%; 0.075%; 0.0375% QID for 14 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Eliminating or reducing clinical signs and symptoms of oral Candida infections.
Time Frame: Day 19
|
Day 19
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the microbiological response of Candida to different concentrations of PAC-113.
Time Frame: Day 19
|
Day 19
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Stomatognathic Diseases
- Mouth Diseases
- Bacterial Infections and Mycoses
- Mycoses
- HIV Infections
- Candidiasis
- HIV Seropositivity
- Candidiasis, Oral
Other Study ID Numbers
- PBC002-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oral Candidiasis
-
Summa Health SystemCompletedOral CandidiasisUnited States
-
University of Santiago de CompostelaNot yet recruitingMicrobial Colonization | Oral Candidiasis | Xerostomia | Radiotherapy; Complications | Candida Albicans Infection | Oral Candidiasis RecurrentSpain
-
Raphael Freitas de SouzaFundação de Amparo à Pesquisa do Estado de São PauloCompletedOral Hygiene | Dental Plaque | Oral Candidiasis | Denture StomatitisBrazil
-
University of FloridaTerminatedHIV Infections | CandidiasisUnited States
-
Raphael Freitas de SouzaCompletedOral Hygiene | Dental Plaque | Oral Candidiasis | Denture StomatitisBrazil
-
Hadassah Medical OrganizationCompletedOral Candidiasis | Denture StomatitisIsrael
-
Hams Hamed AbdelrahmanActive, not recruiting
-
Yasmine gamilCompleted
-
Federal University of the Valleys of Jequitinhonha...UnknownOral Hygiene | Candidiasis, Oral | Behavior | NewbornsBrazil
-
University of BelgradeRecruiting